Evolving Chemotherapies in Glioblastomas(GBM)—Present and Future
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (28 July 2023) | Viewed by 3375
Special Issue Editors
Interests: tumor biology; cell biology; molecular biology
Interests: tumor immunity; cancer biology; metabolism; exosomes; immunotherapy; cell signaling; cellular mechanisms; tumor microenvironment; phage screening; protein–protein interaction; peptide; molecular epigenetics
Special Issue Information
Dear Colleagues,
Glioblastomas (GBM) have remained challenging to treat despite the innovative and revolutionary research taking place worldwide. The current standard of care for GBM, which includes surgery, radiation and chemotherapy with the blood–brain barrier (BBB)-permeable drug temozolomide (TMZ), has not been shown to be capable of extending the median survival time of GBM patients beyond 14.5 months. The response to TMZ is further dampened in O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated patients. The results of various large-scale clinical trials using immune-checkpoint blockades have predicted depressing outcomes for GBM patients. An almost 100% recurrence rate, a highly immunosuppressive environment, heterogeneity and an intact BBB in the peritumoral region of the brain makes most of the therapies ineffective. Various emerging chemotherapy regimens are under development and/or in clinical trials which have shown promise in preclinical models by overcoming the unconducive GBM environment. In this Special Issue, we want to discuss all such chemotherapy-based studies that give hope to patients and to the field of GBM and are the path forward for research into GBM.
Dr. Crismita Dmello
Dr. Fatima Khan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biology
- immunotherapy
- glioblastoma
- brain cancer
- cell signaling
- tumor immunity
- metabolic reprogramming
- exosomes
- receptor and ligand interaction
- peptides
- phage screening